The early luteal hormonal profile in IVF patients triggered with hCG.


Journal

Human reproduction (Oxford, England)
ISSN: 1460-2350
Titre abrégé: Hum Reprod
Pays: England
ID NLM: 8701199

Informations de publication

Date de publication:
01 01 2020
Historique:
received: 14 06 2019
revised: 25 09 2019
pubmed: 23 1 2020
medline: 28 4 2021
entrez: 23 1 2020
Statut: ppublish

Résumé

What is the early luteal phase hormonal profile in patients undergoing ovarian stimulation for IVF/ICSI followed by hCG trigger and a freeze-all strategy without luteal phase support? The peak concentration of progesterone occurred 4 days after oocyte pick-up (OPU + 4), with an average 35% fall from OPU + 4 to OPU + 6, and progesterone levels before and 12 h after hCG administration predicted levels during the early luteal phase. The luteal phase during IVF differs from that during normal cycles, particularly with respect to the serum progesterone level profile. This can cause asynchrony between the embryo and the endometrium, potentially resulting in implantation failure and poor reproductive outcomes. This prospective study included 161 women with normal ovarian reserve receiving GnRH antagonist co-treatment during ovarian stimulation with FSH who were followed up to 6 days after OPU in a single IVF cycle. Women aged 18-42 years undergoing IVF with ovarian stimulation using FSH were included. Ovulation was triggered with recombinant hCG 250 μg. Hormone levels were determined from blood samples taken on the day of trigger, before hCG, at 12, 24 and 36 h after hCG and at 1, 2, 3, 4, 5 and 6 days after OPU. The primary endpoint was early luteal phase serum concentrations of progesterone, LH, estradiol and hCG. One outlier with a pre-hCG serum progesterone level of 11.42 ng/mL was excluded, so all analyses included 160 subjects. Progesterone levels began to increase 1 day after OPU, peaked 4 days after OPU (114 ng/mL), then declined from OPU + 5 onwards. Peak progesterone levels were at OPU + 4, OPU + 5 or OPU + 6 in 38.8, 29.4 and 13.8% of patients, respectively. Approximately two-thirds of patients had a fall in serum progesterone from OPU + 4 to OPU + 6. Pre-hCG progesterone levels correlated significantly with those at 24 h after hCG (r2 = 0.28; P < 0.001), which in turn correlated significantly with progesterone at OPU + 4 (r2 = 0.32; P < 0.001). LH peaked (4.4 IU/L) 12 h after hCG trigger, persisting for 24 h but was barely elevated compared with physiological levels. Serum estradiol peaked twice: at 24 h post-trigger and at OPU + 4. Highest hCG levels (130 mIU/mL) occurred at 24 h post-injection. The best correlations between the number of follicles ≥11 mm and serum progesterone level were seen at 24 and 36 h after hCG and OPU + 1. The influence of different profiles of serum progesterone on reproductive outcomes could not be determined because a freeze-all strategy was used in all patients. In addition, data were not available to relate serum hormone level findings with endometrial histology or endometrial receptivity analysis to clearly identify the relationship between serum hormones and the window of implantation. Detailed information about early luteal phase hormone levels could be used to optimize and individualize luteal phase support to improve reproductive outcomes. This study was funded by My Duc Hospital, Ho Chi Minh City, Vietnam. All authors state that they have no conflicts of interest to disclose. NCT02798146; NCT03174691.

Identifiants

pubmed: 31967304
pii: 5713429
doi: 10.1093/humrep/dez235
doi:

Substances chimiques

Chorionic Gonadotropin 0
Gonadotropin-Releasing Hormone 33515-09-2
Progesterone 4G7DS2Q64Y

Banques de données

ClinicalTrials.gov
['NCT02798146', 'NCT03174691']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

157-166

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.

Auteurs

Lan N Vuong (LN)

Department of Obstetrics and Gynecology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam.
HOPE Research Center, My Duc Hospital, Ho Chi Minh City, Vietnam.

Tuong M Ho (TM)

IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam.
HOPE Research Center, My Duc Hospital, Ho Chi Minh City, Vietnam.

Toan D Pham (TD)

IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam.
HOPE Research Center, My Duc Hospital, Ho Chi Minh City, Vietnam.

Vu N A Ho (VNA)

IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam.
HOPE Research Center, My Duc Hospital, Ho Chi Minh City, Vietnam.

Claus Yding Andersen (CY)

Laboratory of Reproductive Biology, Copenhagen University Hospital and Faculty of Health Science, Copenhagen University, Copenhagen, Denmark.

Peter Humaidan (P)

The Fertility Clinic, Skive Regional Hospital, Skive, Denmark.
Faculty of Health, Aarhus University, Aarhus, Denmark.
Faculty of Health, University of Southern Denmark, Odense, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH